Anikavisc

High viscosity, trusted formula for over 25 years

Anikavisc is a trusted cohesive ophthalmic viscoelastic with over 25 years of proven clinical use. Designed to provide outstanding clarity, excellent chamber stability and endothelial protection, it supports a clear view of the surgical field and controlled performance throughout cataract surgery.

Its highly cohesive properties enable quick and easy removal at the end of the procedure, helping to simplify workflow.

 

 

Anikavisc technical spec.

 

Anikavisc specifications (Avian source, buffered)
Contents Sodium Hyaluronate, Sodium Chloride, Sodium Phosphate Dibasic, Sodium Phosphate Monobasic, Hydrochloric Acid (to adjust pH if necessary), Sodium Hydroxide (to adjust pH if necessary), water for injection and no other ingredients
Appearance Clear, viscous fluid
Identification Conforms to standard spectrum
USP Sterility Test results Sterile, USP
Volume NLT 0.8 mL – NMT 0.94 mL

 

Chemical analysis test results for:
pH 6.8 – 7.6
Dynamic Viscosity @ 1 sec-1, 25°C 40,500 – 46,500 cps
Intrinsic Viscosity 1,750 – 4,000 mL/g
NaHA Concentration 10 – 14 mg/mL
Molecular Weight 1,000,000 – 2,900,000 daltons
Osmolality 288 – 352 mOsm
Protein Concentration ≤ 34 ppm
Galactosamine None detected – limit of detection – 0.050% (w/w)
End Group Analysis Increase in NAG
UV Analysis Conforms to standard spectrum

 

INDICATIONS

Anikavisc is intended for use during surgery in the anterior and posterior segments of the human eye. Procedures include cataract extraction, intraocular lens (IOL) implantation, corneal transplantation surgery, glaucoma filtering surgery and surgical procedures to reattach the retina. Anikavisc is designed to create and maintain anterior chamber depth and visibility, protect corneal endothelial cells and other intraocular tissues, minimize interaction between tissues during surgical manipulation, and act as a vitreous substitute during retinal reattachment surgery. Anikavisc also preserves tissue integrity and good visibility when used to fill the anterior and posterior segments of the eye following open sky procedures.

CONTRAINDICATIONS

At the present time there are no contraindications to the use of Anikavisc when used as recommended.

PRECAUTIONS

Those precautions normally considered during anterior segment and retinal attachment procedures are recommended. Transient increases in intraocular pressure may occur following surgery because of pre-existing glaucoma or due to the surgery itself. For these reasons, the following precautions should be considered. An excess quantity of Anikavisc should not be used. Anikavisc should be thoroughly removed from the anterior chamber after surgery to prevent or minimize post-operative intraocular pressure increases (spikes). If the post-operative intraocular pressure increases above expected values, appropriate therapy should be initiated. Anikavisc is prepared from a biological source and the physician should be aware of the possible effects of using any biological material. A single-use disposable cannula, such as the one provided in the package, should be used when administering Anikavisc. Reuse of the cannula should be avoided. The repeated use of a cannula could release particulate matter as Anikavisc is injected. There have been isolated reports of diffuse particulates or haziness appearing after injection of products similar to Anikavisc into the eye. While such reports are infrequent and seldom associated with any effects on ocular tissues, the physician should be aware of the occurrence. If observed, the particulate matter should be removed by irrigation and/or aspiration.